# Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects

> **NCT01873950** · PHASE1 · COMPLETED · sponsor: **Food and Drug Administration (FDA)** · enrollment: 22 (actual)

## Conditions studied

- Drug-induced Surface ECG Changes

## Interventions

- **DRUG:** Ranolazine
- **DRUG:** Dofetilide
- **DRUG:** Verapamil
- **DRUG:** Quinidine sulfate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01873950
- **Lead sponsor:** Food and Drug Administration (FDA)
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-07
- **Final completion:** 2014-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01873950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01873950, "Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01873950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*